50 clinical presentations and posters
highlight benefits of MRI-guided radiation adaptive therapy
DENVER, May 12, 2023
/PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that
the company's MRIdian MRI-guided radiation therapy system will be
featured at the Annual Meeting of the European Society for
Radiotherapy and Oncology (ESTRO) with over 50 presentations and
posters highlighting MRIdian clinical and research experience. This
year's ESTRO meeting will be held May 12-16,
2023, in Vienna,
Austria.
MRIdian-focused presentations and posters, submitted by MRIdian
clinical teams from across the globe and accepted as part of
ESTRO's Scientific Sessions, highlight MRIdian's clinical value in
treating various cancers, including pancreatic, prostate, liver,
rectal, cervical, and central/ultracentral lung tumors. Additional
topics highlighted include patient satisfaction, cost/benefit
analysis, and single-day MRIdian treatments.
ViewRay will host a lunch symposium on Saturday, May 13, from 13:00 – 14:00 CEST at the Messe Congress Center, Lehar
1-2-3 titled, "MRIdian A3i™*: Transforming MR-guided Radiation
Therapy." The presentation will be given by Drs. Luca Boldrini, Lorenzo
Placidi (Policlinico A. Gemelli), Philip Camilleri, and James Good (GenesisCare Oxford). MRIdian A3i*
adds new treatment delivery features that enhance on-table adaptive
workflow efficiency and expand clinical utility. This
symposium will highlight new MRIdian A3i* features, including MRI
imaging sequences, automated workflow steps, on-table
auto-contouring tools, multiplanar tissue tracking and automated
beam gating, and the ability for clinicians to work collaboratively
during patient treatments.
MRIdian A3i* introduces the 4th generation of real-time tissue
tracking with automatic beam gating, now with multiplanar tracking
and gating. This month marks 11 years
since the introduction of these capabilities, for which MRIdian was
the first system to offer real-time tissue tracking with automatic
beam control following FDA clearance in May
2012.
Visitors to ViewRay's booth #260 can see demonstrations and
presentations of MRIdian A3i* and the new BrainTx package. They can
also hear first-hand experience from clinicians around the world
highlighting MRIdian's benefits in treating a variety of cancers
including:
Saturday, May 13
- Sarcoma treatments and high-value DWI with MRIdian A3i*:
Kujtim Latifi, PhD, Moffitt Cancer Center
- Single fraction liver treatments with MRIdian SMART:
Stefanie Corradini, MD, Ludwig
Maximilian University
Sunday, May 14
- MRIdian A3i* BrainTx™ first experiences:
Rupesh Kotecha, MD, Miami Cancer
Institute
- MRIdian solutions for prostate, lung, and liver:
Juliane Hörner-Rieber, MD, Heidelberg University Hospital
- MRIdian empowers Radiation therapist-driven treatment
workflows: Moran Debby, RTT, Assuta
Medical Center
Monday, May 15
- MRIdian solutions for pancreas cancer: Olivier Riou, MD,
PhD, Institut du Montpellier
- Intensified total neoadjuvant rectum treatments
on MRIdian: Thierry Gevaert,
PhD, Universitair Ziekenhuis Brussel
The MRIdian system provides oncologists with outstanding
anatomical visualization through diagnostic-quality MR images and
the ability to adapt a radiation therapy plan to the targeted
cancer with the patient on the table. This combination allows
physicians to define tight treatment margins to avoid unnecessary
radiation exposure of vulnerable organs-at-risk and healthy tissue
and allows the delivery of ablative radiation doses in five or
fewer treatment sessions without relying on implanted markers.
MRIdian enables automatic gating of the radiation beam if the
target moves outside the user-defined margins by providing
continuous real-time tracking of the target and organs at risk.
This allows for delivering the prescribed dose to the target while
sparing surrounding healthy tissue and critical structures. This
results in minimizing toxicities typically associated with
conventional radiation therapy.
To date, over 31,000 patients have been treated with MRIdian.
Currently, 61 MRIdian systems are installed at hospitals around the
world, where they are used to treat a wide variety of solid tumors
and are the focus of numerous ongoing research efforts. MRIdian has
been the subject of hundreds of peer-reviewed publications,
scientific meeting abstracts, and presentations. For a list of
treatment centers, please visit:
https://viewray.com/mridian-treatment-centers/
* MRIdian A3i features are only available for sale in
the United States and other
limited geographies. MRIdian A3i functions are intended for
educational demonstration purposes only and cannot be made
available until applicable medical device regulations are met.
Disclaimer:
Nothing in this material is intended to provide specific medical
advice or to take the place of written law or regulations.
Safety Statement
The MRIdian Linac System is not
appropriate for all patients, including those who are not
candidates for magnetic resonance imaging. Radiation treatments may
cause side effects that can vary depending on the part of the body
being treated. The most frequent ones are typically temporary and
may include, but are not limited to, irritation to the respiratory,
digestive, urinary, or reproductive systems; fatigue; nausea; skin
irritation; and hair loss. In some patients, side effects can be
severe. Treatment sessions may vary in complexity and duration.
Radiation treatment is not appropriate for all cancers. You should
discuss the potential for side effects and their severity as well
as the benefits of radiation and magnetic resonance imaging with
your doctor to make sure radiation treatment is right for you.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the
MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon
a proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was
purpose-built to address specific challenges, including beam
distortion, skin toxicity, and other concerns that potentially may
arise when high magnetic fields interact with radiation beams.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Private Securities Litigation Reform
Act. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, ViewRay's financial
guidance for the full year 2023, anticipated future
orders, anticipated future operating and financial
performance, treatment results, therapy adoption, innovation, and
the performance of the MRIdian systems. Actual results could
differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, the
ability to commercialize the MRIdian Linac System, demand for
ViewRay's products, the ability to convert backlog into revenue,
the timing of delivery of ViewRay's products, the timing, length,
and severity of the COVID-19 pandemic, including its impacts across
our businesses on demand, our operations and global supply chains,
the results and other uncertainties associated with clinical
trials, the ability to raise the additional funding needed to
continue to pursue ViewRay's business and product development
plans, the inherent uncertainties associated with developing new
products or technologies, competition in the industry in which
ViewRay operates, and overall market conditions. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to ViewRay's business in
general, see ViewRay's current and future reports filed with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K for the fiscal year ended December
31, 2022 and its Quarterly Reports on Form 10-Q, as updated
periodically with the Company's other filings with the SEC. These
forward-looking statements are made as of the date of this press
release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
View original
content:https://www.prnewswire.com/news-releases/viewrays-mridian-to-be-featured-at-leading-european-radiation-oncology-meeting-301821979.html
SOURCE ViewRay, Inc.